Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial, page-286

so does this not worry you in terms of the FDA simply not wanting to approve the product at all and finding more spurious reasons to block approval despite positive COVID results?

ROFL .... you seriously think that if Rem - L was (say) 75% effective in the treatment arm vs (say) 40% survival in the placebo group that with the huge USA daily death toll numbers the FDA would reject it .... especially given the fact that these types of results would make global headlines once released ... pfft !

Then of course you should add to the above scenario the fact that the NIH shelled out $50m USD to support the Rem - L COVID-19 trial and have influence in relation to the FDA and subsequently the footprint of our recent global partner Novartis, and I think you will find you concerns are without merit ? (IMO of course) ... at the very least I believe the FDA would issue an EUA for Rem - L to get the USA through the next 6 months until the vaccines start to show effectiveness across the country; Novartis will take it from there if need be

Finally, the USA isn’t the only country in the world dealing with large COVID-19 daily death numbers, so if Rem - L is effective and they don’t want it, I am sure there will be other countries that will ?